Drug profile · INN
denileukin diftitox-cxdl
LYMPHIR
denileukin diftitox-cxdl (LYMPHIR) is a elongation factor 2 inhibitor. Associated with Citius Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Drug details — denileukin diftitox-cxdl
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
denileukin diftitox-cxdl (LYMPHIR) is a elongation factor 2 inhibitor. Associated with Citius Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Elongation factor 2 inhibitor
Primary target: Elongation factor 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is denileukin diftitox-cxdl?
denileukin diftitox-cxdl (LYMPHIR) is a elongation factor 2 inhibitor. Associated with Citius Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for denileukin diftitox-cxdl?
LYMPHIR is a marketed brand name for denileukin diftitox-cxdl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of denileukin diftitox-cxdl?
denileukin diftitox-cxdl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.